SEC Form 4 · accession 0001628280-26-047507
Crinetics Pharmaceuticals, Inc. · CRNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Coelho Rogerio Vivaldi
Director
Period of report
Jul 2, 2026
Accepted (ET)
Jul 7, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001658247
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 2, 2026 | S | 3,000 | $40.00 | D | 19,225 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.
- F2The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $40.00 per share.